IBDEI1VP ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30009,1,4,0)
 ;;=4^G21.11
 ;;^UTILITY(U,$J,358.3,30009,2)
 ;;=^5003772
 ;;^UTILITY(U,$J,358.3,30010,0)
 ;;=G24.01^^120^1525^15
 ;;^UTILITY(U,$J,358.3,30010,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30010,1,3,0)
 ;;=3^Tardive Dyskinesia
 ;;^UTILITY(U,$J,358.3,30010,1,4,0)
 ;;=4^G24.01
 ;;^UTILITY(U,$J,358.3,30010,2)
 ;;=^5003784
 ;;^UTILITY(U,$J,358.3,30011,0)
 ;;=G24.09^^120^1525^16
 ;;^UTILITY(U,$J,358.3,30011,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30011,1,3,0)
 ;;=3^Tardive Dystonia
 ;;^UTILITY(U,$J,358.3,30011,1,4,0)
 ;;=4^G24.09
 ;;^UTILITY(U,$J,358.3,30011,2)
 ;;=^5003786
 ;;^UTILITY(U,$J,358.3,30012,0)
 ;;=G25.1^^120^1525^11
 ;;^UTILITY(U,$J,358.3,30012,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30012,1,3,0)
 ;;=3^Medication-Induced Postural Tremor
 ;;^UTILITY(U,$J,358.3,30012,1,4,0)
 ;;=4^G25.1
 ;;^UTILITY(U,$J,358.3,30012,2)
 ;;=^5003792
 ;;^UTILITY(U,$J,358.3,30013,0)
 ;;=G25.71^^120^1525^14
 ;;^UTILITY(U,$J,358.3,30013,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30013,1,3,0)
 ;;=3^Tardive Akathisia
 ;;^UTILITY(U,$J,358.3,30013,1,4,0)
 ;;=4^G25.71
 ;;^UTILITY(U,$J,358.3,30013,2)
 ;;=^5003799
 ;;^UTILITY(U,$J,358.3,30014,0)
 ;;=G25.79^^120^1525^9
 ;;^UTILITY(U,$J,358.3,30014,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30014,1,3,0)
 ;;=3^Medication-Induced Movement Disorder,Other
 ;;^UTILITY(U,$J,358.3,30014,1,4,0)
 ;;=4^G25.79
 ;;^UTILITY(U,$J,358.3,30014,2)
 ;;=^5003800
 ;;^UTILITY(U,$J,358.3,30015,0)
 ;;=T43.205A^^120^1525^4
 ;;^UTILITY(U,$J,358.3,30015,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30015,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Init Encntr
 ;;^UTILITY(U,$J,358.3,30015,1,4,0)
 ;;=4^T43.205A
 ;;^UTILITY(U,$J,358.3,30015,2)
 ;;=^5050540
 ;;^UTILITY(U,$J,358.3,30016,0)
 ;;=T43.205D^^120^1525^5
 ;;^UTILITY(U,$J,358.3,30016,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30016,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Subseq Encntr
 ;;^UTILITY(U,$J,358.3,30016,1,4,0)
 ;;=4^T43.205D
 ;;^UTILITY(U,$J,358.3,30016,2)
 ;;=^5050541
 ;;^UTILITY(U,$J,358.3,30017,0)
 ;;=T43.205S^^120^1525^6
 ;;^UTILITY(U,$J,358.3,30017,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30017,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Sequela
 ;;^UTILITY(U,$J,358.3,30017,1,4,0)
 ;;=4^T43.205S
 ;;^UTILITY(U,$J,358.3,30017,2)
 ;;=^5050542
 ;;^UTILITY(U,$J,358.3,30018,0)
 ;;=G25.71^^120^1525^7
 ;;^UTILITY(U,$J,358.3,30018,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30018,1,3,0)
 ;;=3^Medication-Induced Acute Akathisia
 ;;^UTILITY(U,$J,358.3,30018,1,4,0)
 ;;=4^G25.71
 ;;^UTILITY(U,$J,358.3,30018,2)
 ;;=^5003799
 ;;^UTILITY(U,$J,358.3,30019,0)
 ;;=G24.02^^120^1525^8
 ;;^UTILITY(U,$J,358.3,30019,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30019,1,3,0)
 ;;=3^Medication-Induced Acute Dystonia
 ;;^UTILITY(U,$J,358.3,30019,1,4,0)
 ;;=4^G24.02
 ;;^UTILITY(U,$J,358.3,30019,2)
 ;;=^5003785
 ;;^UTILITY(U,$J,358.3,30020,0)
 ;;=G21.0^^120^1525^12
 ;;^UTILITY(U,$J,358.3,30020,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30020,1,3,0)
 ;;=3^Neuroleptic Malignant Syndrome
 ;;^UTILITY(U,$J,358.3,30020,1,4,0)
 ;;=4^G21.0
 ;;^UTILITY(U,$J,358.3,30020,2)
 ;;=^5003771
 ;;^UTILITY(U,$J,358.3,30021,0)
 ;;=T50.905A^^120^1525^1
 ;;^UTILITY(U,$J,358.3,30021,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30021,1,3,0)
 ;;=3^Adverse Effect of Medication,Other,Init Encntr
 ;;^UTILITY(U,$J,358.3,30021,1,4,0)
 ;;=4^T50.905A
